PAREXEL® Access eHub:

Value Through Evidence

Back to Content Hub

Commercial consequences of expedited approval

This paper looks at the results from a payer survey, covering all segments of the payer market and representing 226 million lives, aimed at understanding current and future payer practices.

The Network for Excellence in Healthcare Innovation (NEHI) and PAREXEL jointly completed a research program to understand the impact that Expedited regulatory approval (‘acceleration’) is having on the US payer landscape and the commercial potential of products moving, and not moving, through this pathway. 

 

To achieve this, we completed a payer survey, covering all segments of the payer market and representing 226 million lives, aimed at understanding current and future payer practices. We also reviewed the commercial performance of 26 products, covering 20 accelerated and 6 non-accelerated products across 7 therapy areas. The results are presented in this paper.

Article: Commercial Consequences Of Expedited Approval

Share this: